Vaxcyte officer surrenders 1,020 shares for taxes

Vaxcyte’s Chief Technical Ops Officer reported share withholdings to satisfy taxes on RSU vesting, not open-market sales.

Rhea-AI Filing Summary

Vaxcyte, Inc. (PCVX) reported that Chief Technical Ops Officer Harpreet S. Dhaliwal surrendered shares of common stock to the company to cover tax withholding on vested RSUs. On August 31, 2026, 361 shares were withheld at $60.74 per share, and on September 2, 2026, 659 shares were withheld at $61.58 per share. These are non-market, code F transactions, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Tax Withholding: 1,020 shares

Tax Withholding 2 txns

Insider Dhaliwal Harpreet S.

Role Chief Technical Ops Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	659	$61.58	$41K
Tax Withholding	Common Stock F1	361	$60.74	$22K

Holdings After Transaction: Common Stock — 75,736 shares (Direct)

Footnotes (1)

1. F1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

Key Figures

Shares surrendered for tax withholding: 1,020 shares Shares surrendered on August 31, 2026: 361 shares Per-share value on August 31, 2026: $60.74 per share +2 more

5 metrics

Shares surrendered for tax withholding 1,020 shares Total common shares delivered/withheld for tax liability across both transactions

Shares surrendered on August 31, 2026 361 shares Code F disposition of common stock to cover RSU tax withholding

Per-share value on August 31, 2026 $60.74 per share Value used for 361-share tax-withholding disposition

Shares surrendered on September 2, 2026 659 shares Code F disposition of common stock to cover RSU tax withholding

Per-share value on September 2, 2026 $61.58 per share Value used for 659-share tax-withholding disposition

Key Terms

Restricted Stock Units, tax withholding obligations, vesting

3 terms

Restricted Stock Units financial

"tax withholding obligations realized upon the vesting of RSUs"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares surrendered to the Issuer to cover applicable tax withholding obligations"

vesting financial

"obligations realized upon the vesting of RSUs"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vaxcyte (PCVX) disclose about Harpreet S. Dhaliwal’s recent Form 4 transactions?

The Chief Technical Ops Officer reported two code F transactions, where shares of Vaxcyte common stock were surrendered to the company to cover tax withholding arising from the vesting of RSUs.

How many Vaxcyte (PCVX) shares were surrendered for tax withholding in these transactions?

In total, 1,020 shares of Vaxcyte common stock were surrendered for tax withholding: 361 shares on August 31, 2026 and 659 shares on September 2, 2026.

At what prices were the Vaxcyte (PCVX) shares valued for the tax-withholding dispositions?

The tax-withholding dispositions used per-share values of $60.74 for 361 shares on August 31, 2026 and $61.58 for 659 shares on September 2, 2026.

Were Harpreet S. Dhaliwal’s Vaxcyte (PCVX) transactions open-market sales or part of a 10b5-1 plan?

The transactions are reported as code F share surrenders to pay tax withholding on RSU vesting and not as open-market sales. The Rule 10b5-1 checkbox is not selected, so no trading plan is indicated.

What is the nature of ownership for the Vaxcyte (PCVX) shares in these Form 4 transactions?

Both transactions are reported as direct ownership by Harpreet S. Dhaliwal. The filing does not provide a post-transaction share balance but specifies that the disposed shares were used to cover tax obligations on vested RSUs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 07:56 PM EDT Accepted by SEC EDGAR 09/02/2026 - 07:56 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dhaliwal Harpreet S.

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technical Ops Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/31/2026		F		361(1)	D	$60.74	76,395	D
Common Stock	09/02/2026		F		659(1)	D	$61.58	75,736	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

Remarks:

	Harpreet S. Dhaliwal, by /s/ Peter N. Efremenko, Attorney-In-Fact	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)